❌

Normal view

The Role of Omentin in Gastrointestinal Cancer: Diagnostic, Prognostic, and Therapeutic Perspectives

Metabolites. 2025 Sep 30;15(10):649. doi: 10.3390/metabo15100649.

ABSTRACT

Background/Objectives: Omentin, also known as intelectin-1, is a secreted adipokine with anti-inflammatory, insulin-sensitizing, and immune-modulatory functions, primarily expressed in visceral adipose tissue. While omentin has been associated with favorable metabolic outcomes, its role in cancer pathogenesis appears context-dependent and remains poorly understood. This review investigates the biological functions, expression patterns, and clinical relevance of omentin across gastrointestinal malignancies. Methods: A comprehensive review of the literature was conducted using PubMed, Scopus, and Web of Science up to August 2025 to evaluate the role of omentin in gastrointestinal cancers. Both preclinical and clinical studies evaluating omentin, its analogues and omentin-enhancing agents in gastric, colorectal, hepatic, pancreatic, and esophageal cancers were included. Results: Omentin exhibits anti-proliferative, anti-inflammatory, and anti-angiogenic effects within the tumor microenvironment in several GI malignancies. However, evidence also indicates a dual role. High intratumoral omentin expression correlates with improved prognosis in colorectal, gastric, and hepatic cancers; in contrast, elevated circulating levels-particularly in colorectal and pancreatic cancers-have been paradoxically associated with increased cancer risk and poor outcomes. Mechanistically, omentin modulates PI3K/Akt, NF-κB, AMPK, and oxidative stress pathways, and interacts with TMEM207. However, most available studies are small-scale and heterogeneous, with methodological inconsistencies and limited multi-omics integration, leaving major knowledge gaps. Conclusions: This review highlights omentin's distinct systemic and local roles across GI cancers, underscoring its translational implications. Omentin emerges as a promising but context-dependent biomarker and therapeutic target, with future research needed to address heterogeneity, standardize assays, and validate its clinical utility in large-scale prospective studies.

PMID:41149627 | PMC:PMC12566161 | DOI:10.3390/metabo15100649

Breaking Agent Backbones: Evaluating the Security of Backbone LLMs in AI Agents

arXiv:2510.22620v1 Announce Type: cross Abstract: AI agents powered by large language models (LLMs) are being deployed at scale, yet we lack a systematic understanding of how the choice of backbone LLM affects agent security. The non-deterministic sequential nature of AI agents complicates security modeling, while the integration of traditional software with AI components entangles novel LLM vulnerabilities with conventional security risks. Existing frameworks only partially address these challenges as they either capture specific vulnerabilities only or require modeling of complete agents. To address these limitations, we introduce threat snapshots: a framework that isolates specific states in an agent's execution flow where LLM vulnerabilities manifest, enabling the systematic identification and categorization of security risks that propagate from the LLM to the agent level. We apply this framework to construct the $\operatorname{b}^3$ benchmark, a security benchmark based on 194331 unique crowdsourced adversarial attacks. We then evaluate 31 popular LLMs with it, revealing, among other insights, that enhanced reasoning capabilities improve security, while model size does not correlate with security. We release our benchmark, dataset, and evaluation code to facilitate widespread adoption by LLM providers and practitioners, offering guidance for agent developers and incentivizing model developers to prioritize backbone security improvements.

Benchmarking large language models for personalized, biomarker-based health intervention recommendations

npj Digital Medicine, Published online: 27 October 2025; doi:10.1038/s41746-025-01996-2

Benchmarking large language models for personalized, biomarker-based health intervention recommendations

A Definition of AGI

arXiv:2510.18212v2 Announce Type: replace Abstract: The lack of a concrete definition for Artificial General Intelligence (AGI) obscures the gap between today's specialized AI and human-level cognition. This paper introduces a quantifiable framework to address this, defining AGI as matching the cognitive versatility and proficiency of a well-educated adult. To operationalize this, we ground our methodology in Cattell-Horn-Carroll theory, the most empirically validated model of human cognition. The framework dissects general intelligence into ten core cognitive domains-including reasoning, memory, and perception-and adapts established human psychometric batteries to evaluate AI systems. Application of this framework reveals a highly "jagged" cognitive profile in contemporary models. While proficient in knowledge-intensive domains, current AI systems have critical deficits in foundational cognitive machinery, particularly long-term memory storage. The resulting AGI scores (e.g., GPT-4 at 27%, GPT-5 at 57%) concretely quantify both rapid progress and the substantial gap remaining before AGI.

Quantum cryptography and data protection for medical devices before and after they meet Q-Day

npj Digital Medicine, Published online: 21 October 2025; doi:10.1038/s41746-025-02082-3

Although still at a nascent state, quantum computing promises advances in healthcare, from drug discovery to personalised treatments. But it also threatens current cryptographic systems that protect medical data and infrastructure. The concept of “Q-Day” highlights risks such as “harvest now, decrypt later” attacks, with particular concerns for medical devices and sensitive applications in fields like femtech. Preparing for this future requires the rapid adoption of post-quantum cryptography, the coordination of time-phased and scalable “technology rollout” strategies, and revised regulatory frameworks to safeguard patient safety, privacy, and trust.

Comparative Evaluation of a Medical Large Language Model in Answering Real-World Radiation Oncology Questions: Multicenter Observational Study

Background: Large language models (LLMs) hold promise for supporting clinical tasks, particularly in data-driven and technical disciplines such as radiation oncology. While prior evaluation studies have focused on examination-style settings for evaluating LLMs, their performance in real-life clinical scenarios remains unclear. In the future, LLMs might be used as general AI assistants to answer questions arising in clinical practice. It is unclear how well a modern LLM, locally executed within the infrastructure of a hospital, would answer such questions compared with clinical experts. Objective: This study aimed to assess the performance of a locally deployed, state-of-the-art medical LLM in answering real-world clinical questions in radiation oncology compared with clinical experts. The aim was to evaluate the overall quality of answers, as well as the potential harmfulness of the answers if used for clinical decision-making. Methods: Physicians from 10 departments of European hospitals collected questions arising in the clinical practice of radiation oncology. Fifty of these questions were answered by 3 senior radiation oncology experts with at least 10 years of work experience, as well as the LLM Llama3-OpenBioLLM-70B (Ankit Pal and Malaikannan Sankarasubbu). In a blinded review, physicians rated the overall answer quality on a 5-point Likert scale (quality), assessed whether an answer might be potentially harmful if used for clinical decision-making (harmfulness), and determined if responses were from an expert or the LLM (recognizability). Comparisons between clinical experts and LLMs were then made for quality, harmfulness, and recognizability. Results: There were no significant differences between the quality of the answers between LLM and clinical experts (mean scores of 3.38 vs 3.63; median 4.00, IQR 3.00-4.00 vs median 3.67, IQR 3.33-4.00; P=.26; Wilcoxon signed rank test). The answers were deemed potentially harmful in 13% of cases for the clinical experts compared with 16% of cases for the LLM (P=.63; Fisher exact test). Physicians correctly identified whether an answer was given by a clinical expert or an LLM in 78% and 72% of cases, respectively. Conclusions: A state-of-the-art medical LLM can answer real-life questions from the clinical practice of radiation oncology similarly well as clinical experts regarding overall quality and potential harmfulness. Such LLMs can already be deployed within the local hospital environment at an affordable cost. While LLMs may not yet be ready for clinical implementation as general AI assistants, the technology continues to improve at a rapid pace. Evaluation studies based on real-life situations are important to better understand the weaknesses and limitations of LLMs in clinical practice. Such studies are also crucial to define when the technology is ready for clinical implementation. Furthermore, education for health care professionals on generative AI is needed to ensure responsible clinical implementation of this transforming technology.

Large Language Models’ Clinical Decision-Making on When to Perform a Kidney Biopsy: Comparative Study

Background: Artificial intelligence (AI) and Large Language models (LLMs) are increasing in sophistication and are being integrated into many disciplines. The potential for LLMs to augment clinical decisions is an evolving area of research. Objective: This study compared the responses of over 1000 kidney specialist physicians (nephrologists) to outputs of commonly used LLMs using a questionnaire determining when a kidney biopsy should be performed. Methods: This research group completed a large online questionnaire for nephrologists to determine when a kidney biopsy should be performed. The questionnaire was co-designed with patient participation, refined through multiple iterations, then piloted locally before international dissemination. It was the largest international study in the field and demonstrated variation between human clinicians in biopsy propensity relating to human factors such as sex and age, as well as systemic factors such as country, job seniority and technical proficiency. The same questions were put to both human doctors and LLMs in an identical order in a single session. Eight commonly used LLMs were interrogated: Chat GPT 3.5, Mistral Hugging Face, Perplexity, Microsoft Co-pilot, Llama 2, GPT 4.0, MedLM and Claude 3. The most common response given by clinicians (human mode) to each question was taken as the baseline for comparison. Questionnaire responses to the indications and contraindications for biopsy generated a score (0-44) reflecting biopsy propensity, in which a higher score was used as a surrogate marker for an increased tolerance of potential associated risks. Results: The ability of LLMs to reproduce human expert consensus varied widely with some models demonstrating a balanced approach to risk in a similar manner to humans, whilst other models reported outputs at either end of the spectrum for risk tolerance. In terms of agreement with the human mode, Chat GPT 3.5 and GPT 4.0 (Open AI) had the highest levels of alignment, with the human mode selected in 6/11 questions. The total biopsy propensity score generated from the human mode was 23/44. Both Open AI models produced similar propensity scores between 22 and 24, however Llama 2 and MS Co-pilot also reported scores within this range, but with poorer response alignment to the human mode at only 2/11 questions. The most risk averse model in this study was MedLM with a propensity score of 11 and the least risk averse model was Claude 3 with a score of 34. Conclusions: LLM outputs demonstrated a modest ability to replicate human clinical decision making in this study, however the performance varied widely between LLM models. Questions with more uniform human responses produced LLM outputs with greater alignment, whereas in questions with low levels of human consensus there was poor output alignment. This may limit the practical use of LLMs in real world clinical practice.

STAMP: Single-cell transcriptomics analysis and multimodal profiling through imaging

Single-cell transcriptomics analysis and multimodal profiling (STAMP) by imaging enables single-cell analysis of cells in suspension without the need for sequencing. The markedly reduced costs and flexible experimental designs support the profiling of millions of cells or the large-scale multiplexing of conditions, perturbations, and sample types.

Human interpretable grammar encodes multicellular systems biology models to democratize virtual cell laboratories

We developed a plain text modeling language—a cell behavior hypothesis grammar—to easily build virtual cell models and connect them to data, helping scientists to unlock the hidden dynamics of tissues. We provide examples showing how to use them in virtual experiments exploring how cancer responds to the cells in its environment and how the brain forms layers in development.

Google Gemini: Everything you need to know about the generative AI models

27 February 2025 at 10:09

Gemini is Google’s long-promised, next-gen generative AI model family.

© 2024 TechCrunch. All rights reserved. For personal use only.

  • ✇TechCrunch
  • OpenAI used this subreddit to test AI persuasion Maxwell Zeff
    OpenAI used the subreddit, r/ChangeMyView, to create a test for measuring the persuasive abilities of its AI reasoning models. The company revealed this in a system card — a document outlining how an AI system works — that was released along with its new “reasoning” model, o3-mini, on Friday. Millions of Reddit users are members […] © 2024 TechCrunch. All rights reserved. For personal use only.
     

OpenAI used this subreddit to test AI persuasion

1 February 2025 at 07:47

OpenAI used the subreddit, r/ChangeMyView, to create a test for measuring the persuasive abilities of its AI reasoning models. The company revealed this in a system card — a document outlining how an AI system works — that was released along with its new “reasoning” model, o3-mini, on Friday. Millions of Reddit users are members […]

© 2024 TechCrunch. All rights reserved. For personal use only.

What Trump 2.0 means for science: the likely winners and losers

Nature, Published online: 15 January 2025; doi:10.1038/d41586-025-00052-z

The incoming US president is expected to gut support for research on the environment and infectious diseases, but could buoy work in artificial intelligence, quantum research and space exploration.

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Cancer biomarkers have transformed oncology, enabling treatments tailored to each tumor’s unique profile. This review highlights the field’s progress due to advancements in understanding cancer biology, testing methods, and understanding of the immune microenvironment to advance precision oncology for improved patient outcomes.
❌